pirone 60 mg, and methylphenidate 10 mg (the patient noted that taking methylphenidate 10 mg felt like "being in a roller coaster"). The dose of several medications and the duration and details on whether the patient was on any combination of antidepressants was not available in his medical history. His Patient Health Questionnaire-9 score decreased from 25 to 10 in over a period of 35 weeks. His functioning improved in the following areas: he was able to go out socially with people, get out of the house more often, enjoyed riding his motorcycle, read books, listened to music, and drove on a long distance trip with his friend.
The patient was monitored on a regular basis via phone calls in between regularly scheduled follow-up appointments. Medication titrations were conducted during the phone calls. Interventions from each follow-up visit are shown on Table 1 .
DISCUSSION
When clinicians manage treatmentresistant patients, it is important to do a detailed psychotropic history. Otherwise, they are likely to prescribe medications from the same class that are unlikely to work. Knowing the patient's medication history can allow clinicians to try novel medications, off-label combinations or off-label doses.
There is evidence that the combination of clomipramine, dextroamphetamine, pramipexole, and aripiprazole is safe and effective for TRD. [2] [3] [4] Clinicians have a limited number of options with dopaminergic medications and therefore often neglect to target dopamine. [5] [6] [7] [8] [9] [10] A dopamine transporter photoaffinity ligand, (±)-2-(N-tertButylamino)-3′-[I-125]-iodo-4′-azidopropiophenone, had modest affinity with bupropion. 11 In the (I-123)IBZM single photon emission computed tomography study, atypical antipsychotic drugs, including 30 mg/day of aripiprazole, had no clinical benefit in patients with severe TRD despite their strong oc- case challenge cupancy of dopamine 2 and 3 receptors. 12 An article describing how mesolimbic dopamine regulates motivated behavior was recently published. 13 Commonly used medications to target dopamine in routine clinical practice, such as bupropion and aripiprazole, may have weak dopaminergic action. Hence, greater use of more potent medications such as dextroamphetamine and pramipexole may provide clinicians more options to target dopamine to treat patients with TRD.
